All News
Efficacy of Subsequent b/tsDMARD Use in Rheumatoid Arthritis
Analysis of rheumatoid arthritis (RA) data from the British Society for Rheumatology Biologics Register shows that, even after failing three or more biologic or targeted synthetic DMARDs (b/tsDMARDs), patients may continue to benefit from repeated trials of unused b/tsDMARDs.
Read Article
Allopurinol Use Does Not Increase Mortality in Gout with Chronic Kidney Disease
A population based trial has shown that allopurinol use dose escalation and achieving target uric acid levels (with allopurinol), was not associated with increased mortality in patients with gout and concurrent CKD
Read Article
Trends in Rheumatoid Arthritis Disabililty, Despite Biologics
Disability claims in the U.S. related to rheumatoid arthritis (RA) were just as common in 2015 as in 1999, a government researcher found, against expectations that the advent of biologic therapy would have led to a steady decrease.
Read Article
Upadacitinib FDA Approved for Ankylosing Spondylitis
Abbvie has announced the US Food and Drug Administration has approved upadacitinib (Rinvoq or UPA) for use in adults with active ankylosing spondylitis, who have not responded or been intolerant of one or more TNF blockers. The recommended dose is 15 mg per day.
Read Article
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Links: